Arcutis Biotherapeutics
ARQT
ARQT
93 hedge funds and large institutions have $925M invested in Arcutis Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 19 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
10% less funds holding
Funds holding: 103 → 93 (-10)
12% less capital invested
Capital invested by funds: $1.05B → $925M (-$130M)
43% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 21
Holders
93
Holding in Top 10
3
Calls
$1.38M
Puts
$311K
Top Buyers
| 1 | +$13.5M | |
| 2 | +$5.18M | |
| 3 | +$4.24M | |
| 4 |
BlackRock
New York
|
+$2.45M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$2.3M |
Top Sellers
| 1 | -$13.1M | |
| 2 | -$10.7M | |
| 3 | -$10.4M | |
| 4 |
ACM
Altium Capital Management
New York
|
-$6.09M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.02M |